Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice
The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index.
Abstract
Adeno-associated viral (AAV) vectors promote long-term gene transfer into muscle in many animal species. Increased expression levels may be obtained by using alternative serotypes in combination with repeated administrations. Here we compared AAV vectors based on serotypes 1, 2 and 5 in immunocompetent mice and assessed the feasibility of multiple administrations of either identical (readministration) or different (cross-administration) serotype-based vectors. A 1-year-long dose-response study confirmed the superiority of recombinant (r)AAV1, achieving transduction levels 5 to 10-fold higher than rAAV2 and rAAV5 in mouse skeletal muscle, respectively. Repeated administration demonstrated that increased gene transfer level was achieved with a second injection of rAAV1 following the first administration of rAAV2 or rAAV5. A readministration study with a vector encoding a different gene allowed the evaluation of gene expression from the second vector only. All three rAAVs were inhibited when the animals were previously exposed to the same serotype. In contrast, no significant change in gene expression from the second vector was observed in cross-administration. A humoral immune response was elicited against the viral capsid for all three serotypes following the initial exposure. Neutralizing antibody (NAB) levels correlated with the vector dose injected. No significant cross-reactivity of NAB from a given serotype toward another was observed in vitro. These data provide the first direct comparative evaluation of re- and cross-administration of rAAV1, rAAV2 and rAAV5 in muscle, and further indicate that rAAV1 is capable of transducing muscle tissue when cross-administered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, increased transgene expression in skeletal muscle was observed after AAV1 administration in AAV2- or AAV5pretreated mice (180).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [180]
In the citing paper
“Therefore, using alternative capsid variant with low immunogenicity was shown to be a viable option for achieving ef fi cient transduction in animal studies (178 -184).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [180]
Citations
Cites
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Current Protocols in Human Genetics
(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142905 · Cited by 987
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Immune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654
Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Cited by
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
“1 for AAV2 (Li et al. , 1997), pLT-RC02 for AAV1 (Riviere et al. , 2006), pLT-RC03 for AAV5 (Riviere et al. , 2006), pLTRCO6 for AAV6 (Riviere et al. , 2006), p5e18-VD2-8 for AAV8 (Gao et al. , 2002), and pAAV-2 = 9 for AAV9 (Gao et al. , 2004); and the relevant pAAV2 vector plasmid.”
InfluentialBiological Gene Delivery Vehicles: Beyond Viral Vectors
Seow, Y., & Wood, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.41 · Cited by 327
Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K. A., Fujimoto, N., Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26714-w · Cited by 300
Benchaouir, R., Meregalli, M., Farini, A., D'Antona, G., Belicchi, M., Goyenvalle, A., Battistelli, M., Bresolin, N., Bottinelli, R., Garcia, L., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.09.016 · Cited by 236
“Our approach of using exon-skipping for the expression of human dystrophin within the DMD CD133+ cells should allow the use of the patient’s own stem cells, thus minimizing the risk of immunological graft rejection (Rivière et al., 2006).”
MethodMonteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Metadata
- Authors
- Rivière, C., Danos, O., & Douar, A. M.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Corresponding author
- Douar, A M
- ORCID
- Venue
- Gene Therapy
- Published
- 2006-05-11
- Volume
- 13
- Issue
- 17
- Pages
- 1300-1308
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2078035839
- Cited by
- 192
- References
- 55
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 17 · 2023: 6 · 2022: 15 · 2021: 9 · 2020: 4 · 2019: 6 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 7 · 2014: 6 · 2013: 12 · 2012: 15
- FWCI
- 8.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus vectors, AAV1, AAV2, AAV5, serotype comparison, repeated administration, skeletal muscle gene transfer, long-term gene expression, humoral immune response, neutralizing antibodies, dose-response relationship
- MeSH terms
- Dependovirus, Alkaline Phosphatase, Animals, Antibody Formation, Female, Genetic Vectors, HeLa Cells, Humans, Injections, Intramuscular, Luciferases, Mice, Inbred BALB C, Parvoviridae Infections, Serotyping, Time Factors, Transduction, Genetic, Genetic Therapy, Gene Expression, Muscle, Skeletal, Transgenes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. https://app.cochat.ai/papers/10.1038/sj.gt.3302766
- The paper
- Rivière, C., Danos, O., & Douar, A. M. (2006). Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Therapy. https://doi.org/10.1038/sj.gt.3302766
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.